Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial
| Autor: | Maria Rosa Chitolina Schetinger, Sérgio Luiz Dalmora, Júlia Gomes Farias, N. M. P. Flores, Iria Luiza Gomes Farias, M. C. S. Araújo, Ivana Beatrice Mânica da Cruz, Liana Veronica Rossato, Vera Maria Morsch, M. Durigon, L. I. Elsenbach |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Article Subject Colorectal cancer medicine.medical_treatment Gastroenterology law.invention Randomized controlled trial law Internal medicine Uncaria tomentosa Medicine Adverse effect Chemotherapy Traditional medicine biology business.industry lcsh:Other systems of medicine medicine.disease biology.organism_classification lcsh:RZ201-999 Oxaliplatin Clinical trial Complementary and alternative medicine business Adjuvant medicine.drug Research Article |
| Zdroj: | Evidence-based Complementary and Alternative Medicine : eCAM Evidence-Based Complementary and Alternative Medicine, Vol 2012 (2012) |
| ISSN: | 1741-4288 1741-427X |
| Popis: | To evaluate the effectiveness ofUncaria tomentosain minimizing the side effects of chemotherapy and improving the antioxidant status of colorectal cancer (CRC) patients, a randomized clinical trial was conducted. Patients (43) undergoing adjuvant/palliative chemotherapy with 5-Fluorouracil/leucovorin + oxaliplatin (FOLFOX4) were split into two groups: the UT group received chemotherapy plus 300 mg ofUncaria tomentosadaily and the C group received only FOLFOX4 and served as a control. Blood samples were collected before each of the 6 cycles of chemotherapy, and hemograms, oxidative stress, enzymes antioxidants, immunologic parameters, and adverse events were analyzed. The use of 300 mg ofUncaria tomentosadaily during 6 cycles of FOLFOX4 did not change the analyzed parameters, and no toxic effects were observed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text